TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25179689

Group type: EXPERIMENTAL
Intervention: APF530 250 mg
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: APF530 500 mg
Number of subjects: 1341

Group type: COMPARATOR
Intervention: palonosetron 0.25 mg
Number of subjects: 1341
Study: 24617228

Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture with long needle (75 mm) at Guanyuan (CV 4)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture (40 mm) at Guanyuan (CV 4)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture for postpartum urinary retention
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture for prostate-induced urinary retention
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Deep-oblique acupuncture for orthopedic postoperative urinary retention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture for postpartum urinary retention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture for prostate-induced urinary retention
Number of subjects: 132

Group type: COMPARATOR
Intervention: Regular perpendicular acupuncture for orthopedic postoperative urinary retention
Number of subjects: 132
Study: 22000794

Group type: EXPERIMENTAL
Intervention: Pharyngeal anesthesia with 4 squirts of lidocaine spray
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study: 18060565

Group type: EXPERIMENTAL
Intervention: Piezoelectric ultrasonic device
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Magnetostrictive ultrasonic device
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untreated teeth (control)
Number of subjects: 14
Study: 16563920

Group type: COMPARATOR
Intervention: Intravenous (IV) fenoldopam
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intrarenal (IR) fenoldopam
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intrarenal (IR) fenoldopam (2 hours after drug discontinuation)
Number of subjects: 33
Study: 12062615

Group type: EXPERIMENTAL
Intervention: Two fractions of high-dose-rate brachytherapy (9 Gy per application, 1 week apart)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Concomitant chemotherapy (cisplatin 20 mg/m(2)/day for 5 days during EBRT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Total dose to rectum from high-dose-rate brachytherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Total dose to bladder from high-dose-rate brachytherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Late toxicity
Number of subjects: 49
Study: 10545574

Group type: EXPERIMENTAL
Intervention: Cup-feeding
Number of subjects: 98

Group type: COMPARATOR
Intervention: Bottle-feeding
Number of subjects: 98

Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 98
Study: 7581414

Group type: EXPERIMENTAL
Intervention: Satisfactory stable relationship
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stable relationship
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher occupational social class
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fulfilling social life and job
Number of subjects: 32
Study: 2253662

Group type: EXPERIMENTAL
Intervention: Ibopamine 400 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ibopamine 400 mg t.d.s. for 5 to 10 days
Number of subjects: 80
Study: 483202

Group type: EXPERIMENTAL
Intervention: Bromocriptine 15 mg/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Full medical treatment
Number of subjects: 4
Study: 30043207

Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF 100 µg/kg, single subcutaneous injection 72 hours after chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhG-CSF 5 µg/kg/day, subcutaneous injection once a day for 14 days or until ANC ≥ 10.0 × 10^9/l twice, starting 72 hours after chemotherapy
Number of subjects: 0
Study: 27258925

Group type: EXPERIMENTAL
Intervention: Happy Parenting program
Number of subjects: 119

Group type: COMPARATOR
Intervention: Parent talk (control)
Number of subjects: 119
Study: 25437481

Group type: EXPERIMENTAL
Intervention: Intralase FS 60‐kHz femtosecond laser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralase iFS 150‐kHz femtosecond laser
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 23748286

Group type: EXPERIMENTAL
Intervention: ICNSS for nursing workload estimation and nurse allocation
Number of subjects: 105

Group type: COMPARATOR
Intervention: Equal distribution of sickbeds to nurses
Number of subjects: 105
Study: 20005132

Group type: EXPERIMENTAL
Intervention: Plasma-adapted HES 130/0.42
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonplasma-adapted HES 130/0.42
Number of subjects: 15
Study: 18467724

Group type: EXPERIMENTAL
Intervention: Methylation levels at MINT loci 2, 3, and 31
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Prognostic subclassification based on MINT methylation data
Number of subjects: 251
Study: 17409825

Group type: EXPERIMENTAL
Intervention: Paclitaxel (15 mg/m/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Paclitaxel (6.5 mg/m/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Paclitaxel (17 mg/m/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Continuous infusion of paclitaxel with concurrent radiation therapy (RT)
Number of subjects: 29
Study: 14635510

Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day and nicotine patches
Number of subjects: 88
Study: 10516865

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil in the late in-hospital phase of AMI without heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil in the late in-hospital phase of AMI with heart failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil combined with thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous verapamil in the early phase of AMI
Number of subjects: 0
Study: 8730125

Group type: EXPERIMENTAL
Intervention: DISH patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (DISH-free patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DISH patients with diabetes, dyslipidemia, or hyperuricemia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined metabolic features (DM+DL, DM+HU, DM+DL+HU)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 100
Study: 1655136

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fraxiparine) 41 IU/kg/day for three days, then 62 IU/kg/day from day 4 to day 10
Number of subjects: 349

Group type: COMPARATOR
Intervention: Unfractionated heparin at intervals of eight hours, doses adjusted to maintain activated thromboplastin time at two to five seconds above control values
Number of subjects: 349
Study: 6128021

Group type: EXPERIMENTAL
Intervention: Timolol (0.5-20 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Timolol (27 ng/ml plasma concentration)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Timolol and placebo
Number of subjects: 6
Study: 30852479

Group type: EXPERIMENTAL
Intervention: Mifepristone combined with bevacizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional anticancer drugs
Number of subjects: 60
Study: 29767382

Group type: EXPERIMENTAL
Intervention: TheraCal
Number of subjects: 46

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 46
Study: 26587993

Group type: EXPERIMENTAL
Intervention: Acetazolamide (up to 4 g/d)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 24583571

Group type: EXPERIMENTAL
Intervention: 10 mL/kg of hypertonic saline (HTS) over 1 hour
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 10 mL/kg of hypertonic saline (HTS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 44
Study: 22345317

Group type: EXPERIMENTAL
Intervention: Cold-called smokers who received telephone counseling
Number of subjects: 695

Group type: COMPARATOR
Intervention: Quitline callers
Number of subjects: 695
Study: 20965384

Group type: EXPERIMENTAL
Intervention: Walk Score
Number of subjects: 296
Study: 19076885

Group type: EXPERIMENTAL
Intervention: Oxidized limonene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limonene-1-hydroperoxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure limonene
Number of subjects: 0
Study: 15903129

Group type: EXPERIMENTAL
Intervention: Paroxetine pretreatment (20 mg daily for 3 consecutive days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Paroxetine/tramadol combination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo/tramadol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Paroxetine in combination with placebo
Number of subjects: 16
Study: 12812852

Group type: EXPERIMENTAL
Intervention: 8 Gy radiotherapy (RT)
Number of subjects: 234

Group type: COMPARATOR
Intervention: 20 Gy in five fractions of radiotherapy (RT)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both intervention arms (8 Gy and 20 Gy)
Number of subjects: 234
Study: 10485389

Group type: EXPERIMENTAL
Intervention: Patch test for wheat
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Skin prick test for wheat
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CAP RAST (wheat-specific IgE measurement)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Wheat challenge (double-blind, placebo-controlled or open)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 39

Group type: COMPARATOR
Intervention: Patch test
Number of subjects: 39

Group type: COMPARATOR
Intervention: CAP RAST
Number of subjects: 39
Study: 8799415

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Systemic chemotherapy (mitomycin C and doxorubicin)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No specific anti-cancer treatment
Number of subjects: 57
Study: 1633433

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (Fidia, 300 mg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 6337787

Group type: EXPERIMENTAL
Intervention: Oral verapamil, 240 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Digoxin, 0.25 mg and 0.5 mg daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Digoxin, 0.25 mg and verapamil
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Verapamil alone
Number of subjects: 52
Study: 30975352

Group type: EXPERIMENTAL
Intervention: Patch group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 30278529

Group type: EXPERIMENTAL
Intervention: Yufeining (YFN) treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study: 27128664

Group type: EXPERIMENTAL
Intervention: CHO mouth rinse (6.4% maltodextrin)
Number of subjects: 8
Study: 25219857

Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI‐30, 6086 (BC30)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS) and galactooligosaccharides (GOS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22205316

Group type: EXPERIMENTAL
Intervention: Gustatory stimuli (intensity and hedonics of 5 basic tastes and tastes and odors of foods and nonfoods)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Odor recognition
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Central auditory processing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral assessment of size and shape
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cold pain sensitivity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Body-image dissatisfaction
Number of subjects: 30
Study: 20478383

Group type: EXPERIMENTAL
Intervention: Quercetin 1000 mg/day for 12 weeks
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Quercetin 500 mg/day for 12 weeks
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study: 18034195

Group type: EXPERIMENTAL
Intervention: Treatment B (short exposure, high-energy laser settings): exposure 0.02 s, 300 microm
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment A (conventional settings): exposure time 0.1 s, power sufficient to produce visible grey-white burns, spot size 300 microm
Number of subjects: 20
Study: 15975490

Group type: EXPERIMENTAL
Intervention: 10% MCT fat emulsion (PL:TG 0.06)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% MCT fat emulsion (PL:TG 0.06)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10% MCT/LCT fat emulsion (PL:TG 0.12)
Number of subjects: 30
Study: 12356202

Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living Scale (EADL)
Number of subjects: 240
Study: 10520791

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1920

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1920
Study: 7893502

Group type: EXPERIMENTAL
Intervention: Cytoimmunological monitoring (CIM) after cryopreserved aortic valve implantation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ABO-compatible allografts (group I, n = 9)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ABO-incompatible allografts (group II, n = 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (bioprosthetic valve replacement, n = 8)
Number of subjects: 16
Study: 3162737

Group type: EXPERIMENTAL
Intervention: Experimental treatment focusing on critical features of tooth anatomy and preparation methods
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control treatment with conventional written and oral descriptions
Number of subjects: 192
Study: 29098908

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% topical spray
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.05% topical spray
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vehicle spray
Number of subjects: 34
Study: 27167219

Group type: EXPERIMENTAL
Intervention: 4 weeks ribavirin mono-therapy prior to adding pegIFN-α
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 2 weeks ribavirin double dosing concomitant with pegIFN-α
Number of subjects: 58

Group type: COMPARATOR
Intervention: standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α
Number of subjects: 58
Study: 24480077

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 40
Study: 22660371

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (arm restriction)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 28
Study: 20156473

Group type: EXPERIMENTAL
Intervention: Perceptual learning training (repeated measurements of visual-span profiles at 10 degrees below fixation, in four daily sessions)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 18
Study: 18660549

Group type: EXPERIMENTAL
Intervention: Threshold respiratory-muscle training (RMT) for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-exercising control group (CON)
Number of subjects: 26
Study: 16206003

Group type: EXPERIMENTAL
Intervention: LPLC (7 mmHg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: HPLC (14 mmHg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 12427412

Group type: EXPERIMENTAL
Intervention: Isolated lower-limb training (3 months of low-level bicycle and treadmill exercise, minute ventilation <25 l/min)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Isolated lower-limb training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Guided imagery relaxation techniques (active control)
Number of subjects: 17
Study: 10355231

Group type: EXPERIMENTAL
Intervention: Masked orthographic priming for word targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked repetition priming for nonword targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphological primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked primes
Number of subjects: 0
Study: 8649684

Group type: EXPERIMENTAL
Intervention: 0.2 mg vasopressin diluted with 20 mL saline
Number of subjects: 33

Group type: COMPARATOR
Intervention: 1.5% glycine as the irrigating medium
Number of subjects: 33
Study: 1998874

Group type: EXPERIMENTAL
Intervention: Thyroid isotope scan
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Thyroid ultrasound examination
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Thyroid isotope scans and ultrasound
Number of subjects: 68
Study: 6360739

Group type: EXPERIMENTAL
Intervention: Tromantadine hydrochloride (TH) ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30612833

Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (iNPWT)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 398
Study: 27931259

Group type: EXPERIMENTAL
Intervention: Extracorporeal veno-venous hemoperfusion therapy with the LPS Adsorber
Number of subjects: 32

Group type: COMPARATOR
Intervention: Veno-venous hemoperfusion therapy with a placebo adsorber (without active LPS-binding peptide)
Number of subjects: 32
Study: 25155070

Group type: EXPERIMENTAL
Intervention: Telephone counseling prevention maintenance intervention (PMI) with brief telephone contacts every 8 weeks over 36 months
Number of subjects: 701

Group type: COMPARATOR
Intervention: Time- and dose-consistent PMI focused on general health (comparison condition)
Number of subjects: 701
Study: 21896539

Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m² twice daily for 24 weeks)
Number of subjects: 1987

Group type: COMPARATOR
Intervention: 5-FU/FA (Mayo Clinic regimen)
Number of subjects: 1987
Study: 19356752

Group type: EXPERIMENTAL
Intervention: Urinary gonadotropins
Number of subjects: 231

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 231
Study: 17885017

Group type: EXPERIMENTAL
Intervention: Iron + folate supplements during pregnancy
Number of subjects: 584
Study: 15231011

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6186
Study: 12116053

Group type: EXPERIMENTAL
Intervention: Epinephrine 2.5 mg sublingual tablet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Epinephrine 10 mg sublingual tablet
Number of subjects: 6

Group type: COMPARATOR
Intervention: Epinephrine 0.03 mg IM injection (positive control)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% NaCl IM injection (negative control)
Number of subjects: 6
Study: 9715843

Group type: EXPERIMENTAL
Intervention: ddI (200 mg every 12 hours) alone for 4 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ritonavir (600 mg every 12 hours) alone for 4 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ddI with ritonavir under dose-staggering conditions for 4 days
Number of subjects: 18
Study: 8785890

Group type: EXPERIMENTAL
Intervention: PUVA combined with topical corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PUVA combined with anthralin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PUVA combined with calcipotriene ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PUVA combined with methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PUVA combined with UVB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PUVA combined with retinoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PUVA combined with cyclosporine
Number of subjects: 0
Study: 2281376

Group type: EXPERIMENTAL
Intervention: Conservatively treated patients with pathologic rhizography findings
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Conservatively treated patients with negative rhizography
Number of subjects: 342

Group type: COMPARATOR
Intervention: Surgically treated patients
Number of subjects: 342
Study: 7364841

Group type: COMPARATOR
Intervention: Negative pi meson (pion) radiotherapy at a dose of at least 2700 peak pion rads, delivered at a rate of 100 to 125 rads daily.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional radiation treatment (control group).
Number of subjects: 108
Study: 30725092

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone
Number of subjects: 0
Study: 28759823

Group type: EXPERIMENTAL
Intervention: Pain Resource Nurse program (intervention group)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Wait list control (control group)
Number of subjects: 396
Study: 26556603

Group type: EXPERIMENTAL
Intervention: SRT2104 (three escalating doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25193004

Group type: EXPERIMENTAL
Intervention: DBT-PTSD treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment-as-usual wait-list
Number of subjects: 34
Study: 22571508

Group type: EXPERIMENTAL
Intervention: Short duration tourniquet application (during cement fixation only)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Long duration tourniquet application (from skin incision to just after cement fixation)
Number of subjects: 65
Study: 19395466

Group type: EXPERIMENTAL
Intervention: 1 mg granisetron
Number of subjects: 179

Group type: COMPARATOR
Intervention: 3 mg granisetron
Number of subjects: 179
Study: 17257370

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment (early start)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 15122959

Group type: EXPERIMENTAL
Intervention: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Toronto
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Voucher‐based reinforcement therapy (VBRT) with donations for rewards in Los Angeles
Number of subjects: 0